Showing results (461-470 of 528) with videos related to
Sort By:
Pageof 53
Nature Microbiology|October 14, 2025
Cross-neutralizing and potent human monoclonal antibodies against historical and emerging H5Nx influenza virusesAlexandra A Abu-Shmais, Gray Freeman, Adrian Creanga, et al.Emerging Infectious Diseases|May 20, 2021
Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species LevelVahid Salimi, Mariana Viegas, Alfonsina Trento, et al.Science (New York, N.Y.)|August 3, 2019
A proof of concept for structure-based vaccine design targeting RSV in humansMichelle C Crank, Tracy J Ruckwardt, Man Chen, et al.Nature Biotechnology|January 9, 2018
Functional interrogation and mining of natively paired human VH:VL antibody repertoiresBo Wang, Brandon J DeKosky, Morgan R Timm, et al.Science Translational Medicine|November 2, 2021
A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in miceDavid R Martinez, Alexandra Schäfer, Sophie Gobeil, et al.Iscience|February 3, 2025
MERS-CoV spike vaccine-induced N-terminal domain-specific antibodies are more protective than receptor binding domain-specific antibodiesOlubukola M Abiona, Nianshuang Wang, Sarah R Leist, et al.Science (New York, N.Y.)|June 17, 2020
Broad neutralization of SARS-related viruses by human monoclonal antibodiesAnna Z Wec, Daniel Wrapp, Andrew S Herbert, et al.The New England Journal of Medicine|September 22, 2021
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded PhaseHana M El Sahly, Lindsey R Baden, Brandon Essink, et al.The Lancet. Infectious Diseases|August 11, 2022
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscapeNatalie I Mazur, Jonne Terstappen, Ranju Baral, et al.Cell Reports|October 22, 2020
Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular ProbesTongqing Zhou, I-Ting Teng, Adam S Olia, et al.Pageof 53